Recently, renowned global growth consulting firm Frost & Sullivan (Sullivan) officially published the “2024 Blue Book on Current Status and Trends of the Conjugated Drugs Industry”. This report provides a comprehensive analysis of the industry, examining technical pathways, innovation models, development pipelines, and investment trends. It also offers insightful projections on future directions and potential opportunities within the sector. Thanks to their remarkable technological innovations and breakthroughs in the conjugated drugs field, two companies invested in by Baheal Pharma Group—Radiopharma and Rabpharma—have been highlighted as exemplary case studies in the Blue Book.

On November 25, 2024, BrioHealth Solutions, Inc., a wholly-owned BrioHealth's U.S. subsidiary, announced its independently developed fully magnetic levitation left ventricular assist device, BrioVAD®, had successful completed the first patient enrollment of the INNOVATE clinical trial at Emory University Hospital.

On November 25, 2024, Qingdao Baheal Medical Co., Ltd. (301015.SZ, hereinafter referred to as "Baheal Medical") announced that it has entered an exclusive commercialization partnership with ZAP Surgical Systems, Inc. (hereinafter referred to as "ZAP"), a global leader in radiosurgical robots. This agreement grants Baheal Medical the rights to commercialize ZAP-X® Gyroscopic Radiosurgery Platform and its related accessories in mainland China, Hong Kong, and Macau. This profound collaboration marks Baheal Medical's official entry into the precision radiotherapy market, promoting the clinical application of the world’s first self-shielding radiotherapy device.

November 14, 2024 — Qingdao Baheal Medical INC. (“Baheal Medical”, stock code: 301015.SZ) announced that its wholly-owned subsidiary, Beijing Baheal ZHIHE Medical Achievement Transformation Service Co., Ltd., has signed a marketing cooperation agreement with Beijing Biostar Biopharmaceutical Co., Ltd. (“Biostar”, stock code: 2563.HK). Under the agreement, Baheal Medical will obtain exclusive marketing rights in mainland China for Biostar’s independently developed Class 1 innovative drug, Utidelone Injection (brand name: UTIDE®). Baheal Medical will make a non-refundable upfront payment of RMB 50 million to Biostar, and additional milestone payments based on development and sales progress. In return, Biostar will pay Baheal Pharma a tiered promotion service fee based on annual terminal sales.

Tarcine BioMed, a subsidiary of Baheal Pharma Group, has announced that its independently developed EB Virus Rta Protein IgG Antibody Detection Kit (Chemiluminescent Immunoassay) has been approved by the National Medical Products Administration. This third-generation diagnostic kit for nasopharyngeal cancer, based on a fully automated magnetic particle chemiluminescence platform, offers more stable results and meets diverse clinical diagnostic needs.